I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: July 5, 2007

Signature: /Jeanne M. Brashear/ (Jeanne M. Brashear, Reg. # 56,301)

REPLY UNDER 37 C.F.R § 1.116 EXPEDITED PROCEDURE **TECHNOLOGY CENTER 1645**

Docket No.: 01017/35434B

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Chris Saris

Application No.: 10/622,407

Filed: July 17, 2003

For: Isolation, Identification And Characterization Of

TMST2, A Novel Member Of The TNF-Receptor

Supergene Family

Confirmation No.: 2359

Art Unit: 1645

Examiner: Eileen B. O'Hara, Ph.D.

AMENDMENT AFTER FINAL ACTION UNDER 37 C.F.R. 1.116

MS AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

This paper is in response to the Office Action dated April 5, 2007, finally rejecting claims 40, 41, 49, 50 and 70-73. The present amendment complies with 37 C.F.R. § 1.116(b)(1) and (2) in either eliminating issues for appeal or in placing issues in better form for appeal. Accordingly, the Applicant requests that the Examiner exercise discretion in favor of entering the present amendment. Please amend the above-identified U.S. patent application as follows:

There are no amendments to the specification.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.